Evidence map›Paper›PMID 30286710›Full record

ArticleBMC bioinformatics2018

XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data.

Roelof J C Kluin, Kristel Kemper, Thomas Kuilman, Julian R de Ruiter, Vivek Iyer, Josep V Forment, Paulien Cornelissen-Steijger, Iris de Rink, Petra Ter Brugge, Ji-Ying Song and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Reprogramming of neuronal genome function and phenotype by astrocytes.bioRxiv : the preprint server for biology · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Roelof J C KluinCentral Genomic Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Kristel KemperDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
Thomas KuilmanDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
Julian R de RuiterDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Vivek IyerExperimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
Josep V FormentThe Wellcome Trust/Cancer Research UK (CRUK) Gurdon Institute, University of Cambridge, Cambridge, UK.
Paulien Cornelissen-SteijgerDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.
Iris de RinkCentral Genomic Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Petra Ter BruggeDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ji-Ying SongDivision of Experimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sjoerd KlarenbeekDivision of Experimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ultan McDermottCancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.
Jos JonkersDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Arno VeldsCentral Genomic Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.
David J AdamsDivision of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Daniel S PeeperDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. d.peeper@nki.nl.
Oscar KrijgsmanDivision of Molecular Oncology and Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. o.krijgsman@nki.nl.
The Netherlands Cancer Institute · NLOncode Institute · NLWellcome Sanger Institute · GBUniversity of Cambridge · GB

Funding

Cancer Research UK 21717Wellcome Trust
6 · The paper itself

Abstract

backgroundMouse xenografts from (patient-derived) tumors (PDX) or tumor cell lines are widely used as models to study various biological and preclinical aspects of cancer. However, analyses of their RNA and DNA profiles are challenging, because they comprise reads not only from the grafted human cancer but also from the murine host. The reads of murine origin result in false positives in mutation analysis of DNA samples and obscure gene expression levels when sequencing RNA. However, currently available algorithms are limited and improvements in accuracy and ease of use are necessary.

resultsWe developed the R-package XenofilteR, which separates mouse from human sequence reads based on the edit-distance between a sequence read and reference genome. To assess the accuracy of XenofilteR, we generated sequence data by in silico mixing of mouse and human DNA sequence data. These analyses revealed that XenofilteR removes > 99.9% of sequence reads of mouse origin while retaining human sequences. This allowed for mutation analysis of xenograft samples with accurate variant allele frequencies, and retrieved all non-synonymous somatic tumor mutations.

conclusionsXenofilteR accurately dissects RNA and DNA sequences from mouse and human origin, thereby outperforming currently available tools. XenofilteR is open source and available at https://github.com/PeeperLab/XenofilteR .

Indexed as

AnimalsComputersDatabases, GeneticHigh-Throughput Nucleotide SequencingHumansMiceBreast cancerCancerMelanomaNext-generation sequencing (NGS)Patient-derived xenografts (PDX)SequencingXenograft

Identifiers

PMID30286710
PMCPMC6172735
OpenAlexW2895398843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.